Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Depreciation & Amortization (CF) (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Depreciation & Amortization (CF) for 5 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 11.81% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Dec 2025, down 3.99% year-over-year, with the annual reading at $5.7 million for FY2025, 4.6% down from the prior year.
  • Depreciation & Amortization (CF) hit $1.6 million in Q4 2025 for Krystal Biotech, up from $1.4 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.8 million in Q2 2024 to a low of $536000.0 in Q1 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $1.1 million across 5 years, with a median of $1.1 million in 2022.
  • Biggest five-year swings in Depreciation & Amortization (CF): crashed 30.54% in 2023 and later soared 98.58% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $784000.0 in 2021, then skyrocketed by 38.9% to $1.1 million in 2022, then soared by 39.3% to $1.5 million in 2023, then decreased by 7.91% to $1.4 million in 2024, then rose by 11.81% to $1.6 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for KRYS at $1.6 million in Q4 2025, $1.4 million in Q3 2025, and $1.3 million in Q2 2025.